129 related articles for article (PubMed ID: 32112424)
1. The potentiation of menadione on imatinib by downregulation of ABCB1 expression.
Xiao FY; Zhou FJ; Yuan F; Kuang W; Zhou G; Zhou HH; Cao S
Clin Exp Pharmacol Physiol; 2020 Jun; 47(6):997-1004. PubMed ID: 32112424
[TBL] [Abstract][Full Text] [Related]
2. Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulation.
Ding L; Chen Q; Chen K; Jiang Y; Li G; Chen Q; Bai D; Gao D; Deng M; Zhang H; Xu B
Eur J Pharmacol; 2021 Dec; 913():174633. PubMed ID: 34843676
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic effect of 6-Shogaol in Imatinib sensitive and resistant K562 cells.
Ozkan T; Hekmatshoar Y; Pamuk H; Ozcan M; Yaman G; Yagiz GC; Akdemir C; Sunguroglu A
Mol Biol Rep; 2021 Feb; 48(2):1625-1631. PubMed ID: 33515349
[TBL] [Abstract][Full Text] [Related]
5. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
[TBL] [Abstract][Full Text] [Related]
6. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
[TBL] [Abstract][Full Text] [Related]
7. Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells.
Prado-Carrillo O; Arenas-Ramírez A; Llaguno-Munive M; Jurado R; Pérez-Rojas J; Cervera-Ceballos E; Garcia-Lopez P
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887063
[TBL] [Abstract][Full Text] [Related]
8. Exovesicular-Shh confers Imatinib resistance by upregulating Bcl2 expression in chronic myeloid leukemia with variant chromosomes.
Anusha ; Dalal H; Subramanian S; V P S; Gowda DA; H K; Damodar S; Vyas N
Cell Death Dis; 2021 Mar; 12(3):259. PubMed ID: 33707419
[TBL] [Abstract][Full Text] [Related]
9. Cantharidin Overcomes Imatinib Resistance by Depleting BCR-ABL in Chronic Myeloid Leukemia.
Sun X; Cai X; Yang J; Chen J; Guo C; Cao P
Mol Cells; 2016 Dec; 39(12):869-876. PubMed ID: 27989101
[TBL] [Abstract][Full Text] [Related]
10. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
[TBL] [Abstract][Full Text] [Related]
11. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of
Deng Y; Li X; Feng J; Zhang X
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29559564
[TBL] [Abstract][Full Text] [Related]
13. Emodin Inhibits Resistance to Imatinib by Downregulation of Bcr-Abl and STAT5 and Allosteric Inhibition in Chronic Myeloid Leukemia Cells.
Wang XY; Sun GB; Wang YJ; Yan F
Biol Pharm Bull; 2020; 43(10):1526-1533. PubMed ID: 32999163
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
[TBL] [Abstract][Full Text] [Related]
15. Blockade of the interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to overcome imatinib-resistance of chronic myeloid leukemia cells.
Elgehama A; Chen W; Pang J; Mi S; Li J; Guo W; Wang X; Gao J; Yu B; Shen Y; Xu Q
Cancer Lett; 2016 Mar; 372(1):82-8. PubMed ID: 26721204
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Siah2 Ubiquitin Ligase by Vitamin K3 Attenuates Chronic Myeloid Leukemia Chemo-Resistance in Hypoxic Microenvironment.
Huang J; Lu Z; Xiao Y; He B; Pan C; Zhou X; Xu N; Liu X
Med Sci Monit; 2018 Feb; 24():727-735. PubMed ID: 29400343
[TBL] [Abstract][Full Text] [Related]
17. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
18. Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia.
Cheng R; Huang Y; Fang Y; Wang Q; Yan M; Ge Y
Pharm Biol; 2021 Dec; 59(1):893-903. PubMed ID: 34214017
[TBL] [Abstract][Full Text] [Related]
19. Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells.
Ge Y; Yang B; Xu X; Dai Q; Chen Z; Cheng R
Leuk Lymphoma; 2015 Mar; 56(3):730-8. PubMed ID: 24884318
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
